Salarius Pharmaceuticals Changes Office Address

TL;DR

Salarius Pharma moved offices, check the new address.

AI Summary

Salarius Pharmaceuticals, Inc. filed an 8-K on September 9, 2025, reporting an event on September 4, 2025. The filing indicates a change in the company's principal executive offices to 2450 Holcombe Blvd, Suite X, Houston, TX 77021. The company was formerly known as Flex Pharma, Inc. until July 30, 2014.

Why It Matters

This filing indicates a physical relocation of Salarius Pharmaceuticals' principal executive offices, which could signal operational changes or expansion.

Risk Assessment

Risk Level: low — The filing primarily concerns a change of address for the company's principal executive offices, which is a routine administrative event.

Key Players & Entities

• Salarius Pharmaceuticals, Inc. (company) — Registrant
• September 4, 2025 (date) — Earliest event reported
• 2450 Holcombe Blvd, Suite X, Houston, TX 77021 (location) — New principal executive offices
• Flex Pharma, Inc. (company) — Former company name
• July 30, 2014 (date) — Date of name change

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
• $1.00 — ired to maintain a closing bid price of $1.00 per share or more for at least 10 conse

Filing Documents

• flks-20250904.htm (8-K) — 31KB
• a090925slrxnasdaqcomplianc.htm (EX-99.1) — 16KB
• image_0.jpg (GRAPHIC) — 11KB
• 0001615219-25-000125.txt ( ) — 182KB
• flks-20250904.xsd (EX-101.SCH) — 2KB
• flks-20250904_lab.xml (EX-101.LAB) — 22KB
• flks-20250904_pre.xml (EX-101.PRE) — 13KB
• flks-20250904_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events On September 4, 2025, Salarius Pharmaceuticals, Inc. ("Salarius") received a letter from the Nasdaq Hearings Panel (the "Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") notifying Salarius that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"), as required by the Hearings Panel. To regain compliance with the Bid Price Rule, Salarius' common stock was required to maintain a closing bid price of $1.00 per share or more for at least 10 consecutive business days. Nasdaq further notified Salarius that it will be subject to a Mandatory Panel Monitor for a period of one year from September 4, 2025. If, within that one-year monitoring period, the Listing Qualifications Staff finds Salarius out of compliance with the Bid Price Rule that was the subject of the exception, the Staff will issue a delisting determination letter and Salarius will have the opportunity to request a hearing with the Hearings Panel. The letter notes that Salarius remains noncompliant with Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard") and has until October 20, 2025 to achieve compliance with the Equity Standard per the Hearings Panel's previously announced granting of Salarius' extension request. On September 9, 2025, Salarius issued a press release announcing that that it had regained compliance with the Bid Price Rule. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Salarius Pharmaceuticals, Inc., dated September 9 , 202 5 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: September 9, 2025 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Acting Chief Executive Officer Executive Vice President & Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR